Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
CC transcript
SANTARUS INC (SNTS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/23/2011 BW Santarus Announces Presentation of RHUCIN Clinical Data at 7th C1 Inhibitor Deficiency Workshop
05/04/2011 BW Santarus Reports First Quarter 2011 Financial Results
05/03/2011 BW Santarus Announces Oral Presentations of Budesonide MMX Phase III Data at Digestive Disease Week Meeting
04/21/2011 BW Santarus to Hold First Quarter 2011 Financial Results Conference Call on May 4
03/21/2011 BW Santarus and Pharming Announce RHUCIN Poster at American Academy of Allergy, Asthma & Immunology 2011 Annual Meeting
03/10/2011 BW Santarus Initiates Phase I Clinical Study with SAN-300
03/03/2011 BW Santarus Reports Fourth Quarter and Full Year 2010 Financial Results
03/01/2011 BW Santarus to Present at March Investment Conferences
02/28/2011 BW Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
02/22/2011 BW Santarus to Hold Fourth Quarter and Full Year 2010 Financial Results Conference Call on March 3
02/22/2011 BW Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
11/23/2010 BW Santarus to Present at Piper Jaffray 22nd Annual Health Care Conference
11/15/2010 BW Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
11/08/2010 BW Santarus Reports Third Quarter 2010 Financial Results
11/08/2010 BW Santarus Announces Positive Top-Line Results in E.U. Phase III Clinical Study Evaluating Budesonide MMX in Ulcerative Colitis
11/04/2010 BW Cycloset Data to Be Presented in Poster Session at 8th Annual World Congress on Insulin Resistance, Diabetes & CVD
10/27/2010 BW Santarus to Hold Third Quarter 2010 Financial Results Conference Call on November 8
09/29/2010 BW Santarus and Cosmo Announce Positive Top-Line Results in U.S. Phase III Clinical Study Evaluating Budesonide MMX in Ulcerative Colitis
09/13/2010 BW Santarus Adds Two Novel Biologic Drug Candidates to Pipeline
09/09/2010 BW Santarus to Present at September Investment Conferences
09/08/2010 BW Santarus Licenses Novel Type 2 Diabetes Drug CYCLOSET
08/30/2010 BW Santarus Extends Maturity of $25 Million Revolving Line of Credit to July 2013
08/02/2010 BW Santarus Reports Second Quarter 2010 Financial Results
07/26/2010 BW Santarus to Hold Second Quarter 2010 Financial Results Conference Call on August 2
06/30/2010 BW Santarus Announces Launch of Prescription ZEGERID Authorized Generic and Company Restructuring
05/06/2010 BW Santarus Reports First Quarter 2010 Financial Results
04/28/2010 BW Santarus to Hold First Quarter 2010 Financial Results Conference Call on May 6
04/14/2010 BW Santarus Announces District Court Ruling in Par Litigation
03/25/2010 BW Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
03/03/2010 BW Santarus Reports Fourth Quarter and Full Year 2009 Financial Results
02/25/2010 BW Santarus to Present at March Investment Conferences
02/17/2010 BW Santarus to Hold Fourth Quarter and Full Year 2009 Financial Results Conference Call on March 3

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy